PiaSky Side Effects

Generic name: crovalimab

Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.

Note: This document provides detailed information about PiaSky Side Effects associated with crovalimab. Some dosage forms listed on this page may not apply specifically to the brand name PiaSky.

Applies to crovalimab: parenteral injection for iv use, parenteral injection for sub-q use.

Important warnings This medicine can cause some serious health issues

REMS:

FDA approved a REMS for crovalimab-akkz to ensure that the benefits outweigh the risks.¹ The REMS may apply to one or more preparations of crovalimab-akkz and consists of the following: elements to ensure safe use and implementation system.

See the FDA REMS page ([Web]) for specific information.¹

Side effects include:

Adverse effects (≥10%): Infusion-related reactions, respiratory tract infections, viral infections, type III hypersensitivity reactions.

For healthcare professionals

Applies to crovalimab: injectable solution.

General adverse events

The most common adverse reactions occurring in at least 10% of patients who were either treatment naive or previously treated with a complement C5 inhibitor included infusion-related reaction, respiratory tract infection, and viral infection.^[Ref]

Dermatologic

• Common (1% to 10%): Rash/skin exfoliation

Gastrointestinal

• Common (1% to 10%): Diarrhea (including infectious), nausea

Hypersensitivity

• Very common (10% or more): Type III hypersensitivity reaction In patients switching from this drug to another C5 inhibitor (up to 25%), type III hypersensitivity reaction In patients switching from another C5 inhibitor to this drug (up to 19.4%), infusion-related reaction including anaphylaxis (up to 16%)
• Common (1% to 10%): Injection-related or injection-site reaction

Adverse reactions/symptoms associated with Type III hypersensitivity reactions included arthralgia, rash, pyrexia, myalgia, headache, fatigue, petechiae, abdominal pain, and renal abnormalities.

Infusion-related reactions or systemic injection-related reactions may include hypersensitivity reactions (including anaphylaxis) but also a range of other symptoms such as injection-site pain, erythema, headache, or myalgia.

Metabolic

• Common (1% to 10%): Hyperuricemia

Musculoskeletal

• Common (1% to 10%): Arthralgia

Nervous system

• Very common (10% or more): Headache/migraine (up to 11%)

Other

• Very common (10% or more): Viral infections including COVID-19, influenza, RSV, and herpes (up to 23%), peripheral edema/swelling (up to 11%)
• Common (1% to 10%): Fatigue/malaise/asthenia

Respiratory

• Very common (10% or more): Respiratory tract infection (up to 18%)

Respiratory tract infections included nasopharyngitis, pharyngitis, rhinitis, rhinitis allergic, upper respiratory tract infection, and pneumonia.

Further information

PiaSky side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer